• Home
  • Search
  • Dynamics and durability of HIV-1 neutralization are determined by viral replication
  • Cite Icon16
  • https://doi.org/10.1038/s41591-023-02582-3Copy DOI Icon

Dynamics and durability of HIV-1 neutralization are determined by viral replication

Show More
  • Abstract
  • Highlights & Summary
  • PDF
  • Literature Map
  • References
  • Citations
  • Similar Papers
Abstract

Human immunodeficiency virus type 1 (HIV-1)-neutralizing antibodies (nAbs) that prevent infection are the main goal of HIV vaccine discovery. But as no nAb-eliciting vaccines are yet available, only data from HIV-1 neutralizers—persons with HIV-1 who naturally develop broad and potent nAbs—can inform about the dynamics and durability of nAb responses in humans, knowledge which is crucial for the design of future HIV-1 vaccine regimens. To address this, we assessed HIV-1-neutralizing immunoglobulin G (IgG) from 2,354 persons with HIV-1 on or off antiretroviral therapy (ART). Infection with non-clade B viruses, CD4+ T cell counts <200 µl−1, being off ART and a longer time off ART were independent predictors of a more potent and broad neutralization. In longitudinal analyses, we found nAb half-lives of 9.3 and 16.9 years in individuals with no- or low-level viremia, respectively, and 4.0 years in persons who newly initiated ART. Finally, in a potent HIV-1 neutralizer, we identified lower fractions of serum nAbs and of nAb-encoding memory B cells after ART initiation, suggesting that a decreasing neutralizing serum activity after antigen withdrawal is due to lower levels of nAbs. These results collectively show that HIV-1-neutralizing responses can persist for several years, even at low antigen levels, suggesting that an HIV-1 vaccine may elicit a durable nAb response.

Loading PDF

Similar Papers
  • PDF
  • Discussion
  • Citations12

The Cat and Mouse of HIV-1 Antibody Escape

  • Sep 18, 2009
  • PLoS Pathogens
  • John R Mascola
  • Research Article
  • Citations230

Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.

  • Mar 15, 2010
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • D Mcmahon +12
  • Research Article
  • Citations84

Emergence of Multiclass Drug–Resistance in HIV‐2 in Antiretroviral‐Treated Individuals in Senegal: Implications for HIV‐2 Treatment in Resouce‐Limited West Africa

  • Feb 15, 2009
  • Clinical Infectious Diseases
  • Geoffrey S Gottlieb +16
  • Discussion
  • Citations1

Underquantification of plasma HIV-1 RNA levels in a cohort of newly-diagnosed individuals

  • Mar 30, 2010
  • International Journal of Infectious Diseases
  • Philippe Colson +2
  • PDF
  • Supplementary Content
  • Citations10

Driving HIV-1 into a Vulnerable Corner by Taking Advantage of Viral Adaptation and Evolution

  • Mar 16, 2017
  • Frontiers in Microbiology
  • Shigeyoshi Harada +1
  • Research Article
  • Citations9

Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies

  • Nov 29, 1999
  • Vaccine
  • Geoffrey J Gorse +3
  • PDF
  • Research Article
  • Citations16

Comparative Evaluation of HIV-1 Neutralization in External Secretions and Sera of HIV-1-Infected Women

  • Dec 28, 2012
  • The Open AIDS Journal
  • Qing Wei +5
  • Research Article
  • Citations39

Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1

  • Nov 17, 2009
  • Virology
  • Avishek Nandi +12
  • Research Article
  • Citations16

Pseudotypes of vesicular stomatitis virus‐bearing envelope antigens of certain HIV‐1 strains permissively infect human syncytiotrophoblasts cultured in vitro: Implications for in vivo infection of syncytiotrophoblasts by cell‐free HIV‐1

  • Jul 13, 2001
  • Journal of Medical Virology
  • Attila Bácsi +6
  • Research Article
  • Citations80

Increased thymic output after initiation of antiretroviral therapy in human immunodeficiency virus type 1-infected children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 Trial.

  • Jul 05, 2002
  • The Journal of Infectious Diseases
  • Anita De Rossi +5
  • Research Article
  • Citations7

Conformation of HIV-1 Envelope Governs Rhesus CD4 Usage and Simian-Human Immunodeficiency Virus Replication.

  • Jan 11, 2022
  • mBio
  • Geraldine Vilmen +6
  • Research Article
  • Citations69

Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection.

  • Aug 26, 2003
  • Journal of Virology
  • Leor S Weinberger +2
  • PDF
  • Supplementary Content
  • Citations196

The Role of Macrophages in HIV-1 Persistence and Pathogenesis

  • Dec 05, 2019
  • Frontiers in Microbiology
  • Zita Kruize +1
  • Dissertation

Immunogenicity of a PCR-based humanized HIV envelope DNA vaccine in mice

  • Jan 01, 2003
  • Sunee Sirivichayakul
  • Research Article
  • Citations21

Interleukin-1β Triggers p53-Mediated Downmodulation of CCR5 and HIV-1 Entry in Macrophages through MicroRNAs 103 and 107

  • Sep 29, 2020
  • mBio
  • Robert Lodge +8
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.